Mesoblast (MEOBF) Stock Price, News & Analysis

Company Overview

Mesoblast Limited is an Australia-based biotechnology company that develops allogeneic cellular medicines designed to treat serious inflammatory and immune-mediated conditions. Its technology is based primarily on mesenchymal lineage cells, which are intended to regulate immune responses, reduce inflammation and support tissue repair without requiring cells to be collected from the individual patient.

The company’s lead product, remestemcel-L, is marketed in the United States under the brand name Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. Mesoblast is also developing cellular therapies for conditions including chronic heart failure, chronic low back pain and other inflammatory disorders. Its programs have included products administered directly into affected tissues as well as intravenous therapies.

Mesoblast was founded in 2004 and is headquartered in Melbourne, Australia, with operations and clinical development activities in the United States and other international markets. The company’s leadership has included Silviu Itescu, a physician and biotechnology executive who co-founded Mesoblast and has served as its chief executive officer.

Key Stats

• Today's Range: $1.32 to $1.32
• 50-Day Range: $1.14 to $1.90
• 52-Week Range: $1.14 to $2.59
• Volume: N/A
• Average Volume: 57,450 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MEOBF
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A